Evidence map›Paper›PMID 40913650›Full record

Trial reportArchives of gynecology and obstetrics2025

The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial.

Shahideh Jahanian Sadatmahalleh, Fatemeh Razavinia, Razieh Lotfi, Fariba Hajimoosayi, Malihe Nasiri, Parvaneh Rezasoltani

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shahideh Jahanian SadatmahallehDepartment of Reproductive Health and Midwifery, Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Jalal Al-Ahmad HighwayNasr Bridge, Tehran, 14115-111, Iran. Shahideh.Jahanian@modares.ac.ir.ORCID 0000-0002-7006-8487
Fatemeh RazaviniaSexual And Reproductive Health Research Center, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-6827-509X
Razieh LotfiSocial Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran.ORCID 0000-0003-4785-4065
Fariba HajimoosayiDepartment of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID 0009-0000-7248-0101
Malihe NasiriDepartment of Basic Sciences, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1496-7442
Parvaneh RezasoltaniDepartment of Midwifery, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran.ORCID 0000-0003-0515-4044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolycystic ovary syndrome (PCOS) is characterized by reproductive and endocrine abnormalities.

objectiveThe present study aimed to assess the effect of oral contraceptive pills (OCPs) and vitamin D3 on sexual dysfunction in women with PCOS and vitamin D3 deficiency. MATERIALS AND

methodsThis randomized double-blind placebo-controlled clinical trial was conducted in Iran between January and April 2019. The Female Sexual Function Index (FSFI) and Beck Depression Inventory (BDI) questionnaires were filled out for all participants and their serum levels of vitamin D3 were measured. Women with PCOS and vitamin D3 deficiency were divided into 2 equal groups (A and B) with a table of random numbers (n = 35/ each). Both groups were given vitamin D3 (50,000 IU/w) for 12 week. The case group was given low-dose OCP for 3 months and a similar placebo was given to the control group. Vitamin D3 level and sexual function were assessed in both groups at 3 and 6 months after taking OCP.

resultsThere was no statistically significant difference between the two groups in demographic characteristic such as weight (69.54 ± 10.34 vs 70.17 ± 10.60, P = 0.803). Both groups treated with vitamin D3 exhibited increased sexual function scores at the beginning of the study (P = 0.03) and 3 months (P = 0.01) after taking OCP. Examination of sexual function variables showed that sexual desire in the control group was greater than in the OCP-treated group at 3 (P = 0.009) and 6 (P = 0.01) months after entering the study.

conclusionThe results of the study showed that the score of women's sexual performance increased in all areas, especially in the area of sexual desire, with the use of vitamin D3. The simultaneous use of OCP with vitamin D3 to improve sexual performance in these women had no significant difference with the use of vitamin D3 alone. According to the research findings, it is recommended that vitamin D3 supplementation can be used to increase the quality of life and improve sexual function in PCOS women.

Indexed as

CholecalciferolContraceptives, Oral, HormonalPolycystic Ovary SyndromeSexual Dysfunction, PhysiologicalAdultDietary SupplementsDouble-Blind MethodFemaleHumansIranYoung AdultCholecalciferolContraceptives, Oral, HormonalOCPPCOSSexual dysfunctionVitamin D

Identifiers

PMID40913650
PMCPMC12589240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.